Teva Pharmaceutical Industries Ltd., Actavis plc, and Mylan Inc.: Generic Drug Companies to Buy or Avoid?

Actavis, Teva, and Mylan, which generic drug makers should be on your radar?

Jan 7, 2014 at 6:05PM

Teva Pharmaceuticals (NYSE:TEVA), Actavis (NYSE:AGN), and Mylan (NASDAQ:MYL) are all generic drug manufacturers, and with the exception of Teva, stock performance within this class has been tremendous over the last two years. Looking ahead, is it possible that generic drug stocks are a continued buying opportunity?

The patent cliff
According to a February 2011 research report by Evaluate Pharma , approximately $133 billion in brand drug sales would lose patent protection in a six-year period between 2011 and 2017. This period has been labeled the patent cliff by many who follow the sector.

There have been many effects as a result of the patent cliff. First, large pharma sales have suffered or are expected to suffer in the coming years. Second, the cliff has forced large pharma into big acquisitions and record spending in R&D. Third, we've seen a paradigm shift and new leaders in the sector emerge, such as Gilead and Celgene. Lastly, generic drug manufacturers have thrived.

2014: An exceptional year ahead?
The last effects are the ones that aren't often discussed, but could be most lucrative for investors. To explain, take a look at the chart below, showing a top-nine list of blockbusters-only that are expected to lose patent protection in 2014 alone

Company

Drug

Annual Sales

AstraZeneca

Nexium  

$4.9 billion

Eli Lilly

Cymbalta

$4 billion

Teva

Copaxone 

$4 billion

AstraZeneca

Symbicort 

$3.1 billion

GD Searles

Celebrex 

$2.5 billion

Novartis

Sandostatin 

$1.3 billion

Merck

Nasonex 

$1.3 billion

AbbVie

Trilipix 

$1.1 billion

Eli Lilly

Evista 

$1 billion

Total

 

$59.2 billion

Source: FiercePharma.

In 2014 alone, more than 40% of Evaluate Pharma's estimated $133 billion in brand drug sales will lose patent protection. Thus, 2014 is the biggest single year of the patent cliff, at least for generic drug manufacturers and pharmacies.

Moreover, if we look further, Abilify ($4.6 billion) and Gleevec ($4.3 billion) are expected to lose patent protection in 2015 , then Crestcor ($6 billion) and Benicar ($2.5 billion) in 2016 .

Hence, it is going to be an exceptional year for generic drug manufacturers, especially Mylan and Actavis.

Winner and losers of the patent cliff
In 2013, generics were actually a weakness for Mylan, as North American generic sales fell 14% in the company's third quarter . The company went through a transition where it lost generic exclusivity, and lost blockbuster generic rights to Actavis. With that said, Mylan has seen strength in global generic sales, rising 11% in its last quarter, and judging by analysts, the company is expected to have a much better year as more generic drugs hit the market.

Actavis has been the big winner of the patent cliff. Its pharma business grew 69% in its last quarter, and the company notes that much of that growth was due to new generic launches such as Suboxone, Nucynta, Lamictal, and Lidoderm, which were all big patent expirations in late-2012 to 2013. Looking ahead, Actavis is expecting far more blockbuster generic launches, as analysts expect sales to grow 22% this year.

Teva is the wild card, because although generics have done well, the company also faces the challenge of losing patent protection on its single largest drug Copaxone. As fate would have it, Copaxone has been a reason for constant concern among shareholders, as it accounts for 20% of the company's total annual sales.

Is it time to buy generic-drug makers?
Like all industries, every company presents different levels of value.

Unsurprisingly, Teva is expected to post a 1.5% year-over-year revenue loss in 2014. While it may be too early to gauge the full effect of losing patent exclusivity on Copaxone, a 1.5% loss seems reasonable, and likely implies growth in the company's generic business. At 1.7 times sales, Teva is the cheapest in the space, but because of Copaxone, the company will fail to produce significant growth during a time when generic drug makers should thrive. For this reason, it's hard to be bullish on Teva.

Mylan trades at 2.4 times sales and is expecting revenue growth of 12.4% in 2014. Actavis, while more expensive at 3.8 times sales, is also expected to grow significantly faster at 22% in 2014 . Therefore, either Actavis or Mylan look like solid investment opportunities based on growth. Both trade at near 13 times forward earnings, thus are relatively cheap, allowing investors to take advantage of a hyper-growth industry with attractive valuations. Essentially, these two stocks should thrive in 2014, and beyond.

2 game-changing biotechs to watch now
The best way to play the biotech space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In the Motley Fool's brand-new FREE report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.

Brian Nichols has no position in any stocks mentioned. The Motley Fool recommends Teva Pharmaceutical Industries. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.


Compare Brokers